Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input
This article was originally published in The Tan Sheet
Executive Summary
FDA will consider "public comment of the widest kind" from the "layperson to health professionals to scientists" in analyzing and changing portions of the June 1997 proposed rule on ephedrine alkaloids in dietary supplements, Commissioner Jane Henney, MD, testified at a congressional hearing Feb. 29.
You may also be interested in...
Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
FDA's decision to ban ephedra outright creates a win-win situation for the agency, regardless of whether the regulation stands up in court
Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
FDA's decision to ban ephedra outright creates a win-win situation for the agency, regardless of whether the regulation stands up in court
Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
FDA's decision to ban ephedra outright creates a win-win situation for the agency, regardless of whether the regulation stands up in court